AIM: To determine the benefit of surgery for resectable pancreatic adenocarcinomas (PAs) in elderly patients. METHODS: From 2004 to 2009, 932 patients with resectable PAs underwent pancreatectomies without neoadjuvant treatment in 37 institutions. The patients were divided into three groups according to age: <70 years (control group; n = 580); 70-79 years (70s group, n = 288), and ≥ 80 years (80s group; n = 64). Preoperative, intraoperative, postoperative, and histological data were recorded to assess the postoperative course and survival. RESULTS: Preoperative or intraoperative characteristics, and the histological findings were comparable in the three groups. Postoperative mortality and morbidity rates did not differ in the three groups. Adjuvant therapies were more frequently used in younger patients than in elderly patients (p < 0.01). The overall 1-year, 3-year, and 5-year survival rates of control group/70's group/80's group were 82.2%/75.7%/75.7%, 49.9%/41.8%/31%, and 38.7%/33.2%/0%, respectively (p = 0.16). The median survival of the control, 70s, and 80s groups was 24 months, 35.3 months, and 30 months, respectively. Four independent prognostic indicators were identified by multivariate analysis: venous invasion (hazard ratio (HR) = 2.12), arterial invasion (HR = 2.96), positive lymph nodes (HR = 2.25), and adjuvant treatment (HR = 0.65). CONCLUSIONS: Fit elderly patients with resectable PAs should not be excluded from surgical resection of PA solely because of their real age. Moreover, elderly patients seem to obtain similar advantages from pancreatectomies than younger patients.
AIM: To determine the benefit of surgery for resectable pancreatic adenocarcinomas (PAs) in elderly patients. METHODS: From 2004 to 2009, 932 patients with resectable PAs underwent pancreatectomies without neoadjuvant treatment in 37 institutions. The patients were divided into three groups according to age: <70 years (control group; n = 580); 70-79 years (70s group, n = 288), and ≥ 80 years (80s group; n = 64). Preoperative, intraoperative, postoperative, and histological data were recorded to assess the postoperative course and survival. RESULTS: Preoperative or intraoperative characteristics, and the histological findings were comparable in the three groups. Postoperative mortality and morbidity rates did not differ in the three groups. Adjuvant therapies were more frequently used in younger patients than in elderly patients (p < 0.01). The overall 1-year, 3-year, and 5-year survival rates of control group/70's group/80's group were 82.2%/75.7%/75.7%, 49.9%/41.8%/31%, and 38.7%/33.2%/0%, respectively (p = 0.16). The median survival of the control, 70s, and 80s groups was 24 months, 35.3 months, and 30 months, respectively. Four independent prognostic indicators were identified by multivariate analysis: venous invasion (hazard ratio (HR) = 2.12), arterial invasion (HR = 2.96), positive lymph nodes (HR = 2.25), and adjuvant treatment (HR = 0.65). CONCLUSIONS: Fit elderly patients with resectable PAs should not be excluded from surgical resection of PA solely because of their real age. Moreover, elderly patients seem to obtain similar advantages from pancreatectomies than younger patients.
Authors: Natalie Liu; Daniela Molena; Miloslawa Stem; Amanda L Blackford; David B Sewell; Anne O Lidor Journal: J Gastrointest Surg Date: 2018-02-05 Impact factor: 3.452
Authors: M Adham; L C Bredt; M Robert; J Perinel; C Lombard-Bohas; T Ponchon; P J Valette Journal: Langenbecks Arch Surg Date: 2014-03-27 Impact factor: 3.445
Authors: Natalie Liu; Yiwei Xu; Amir A Rahnemai-Azar; Daniel E Abbott; Sharon M Weber; Anne O Lidor Journal: J Gastrointest Surg Date: 2019-12-02 Impact factor: 3.452
Authors: Pietro Addeo; Jean Robert Delpero; Francois Paye; Elie Oussoultzoglou; Pascal R Fuchshuber; Alain Sauvanet; Antonio Sa Cunha; Yves Patrice Le Treut; Mustapha Adham; Jean-Yves Mabrut; Laurence Chiche; Philippe Bachellier Journal: HPB (Oxford) Date: 2013-03-06 Impact factor: 3.647
Authors: Jose M Pimiento; Ashley H Davis-Yadley; Richard D Kim; Dung-Tsa Chen; Edward A Eikman; Claudia G Berman; Mokenge P Malafa Journal: Clin Nucl Med Date: 2016-03 Impact factor: 7.794
Authors: M T Huggett; M Jermyn; A Gillams; R Illing; S Mosse; M Novelli; E Kent; S G Bown; T Hasan; B W Pogue; S P Pereira Journal: Br J Cancer Date: 2014-02-25 Impact factor: 7.640